Organizational structure

12 Months Ended

Mar. 31, 2026

Disclosure Of Significant Investments In Subsidiaries Associates And Joint Ventures [Abstract]

37.

Organizational structure

Dr. Reddy’s Laboratories Limited is the parent company. Tabulated below is the list of subsidiaries, joint ventures and associates as of March 31, 2026:

Name of the subsidiaries/associates/joint ventures	Country of Incorporation	Percentage of Direct/Indirect Ownership Interest
Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.	Malaysia	100% (1)
Aurigene Oncology Limited ( Formerly, Aurigene Discovery Technologies Limited)	India	100%
Aurigene Pharmaceutical Services Limited	India	100% (1)
beta Institut gemeinnützige GmbH	Germany	100% (6)
betapharm Arzneimittel GmbH	Germany	100% (6)
Cheminor Investments Limited	India	100%
Dr. Reddy’s Farmaceutica Do Brasil Ltda.	Brazil	100%
Dr. Reddy’s Laboratories (EU) Limited	United Kingdom	100% (7)
Dr. Reddy’s Laboratories (Proprietary) Limited	South Africa	100% (7)
Dr. Reddy’s Laboratories (UK) Limited	United Kingdom	100% (3)
Dr. Reddy’s Laboratories Canada, Inc.	Canada	100% (7)
Dr. Reddy’s Laboratories Chile SPA.	Chile	100% (7)
Dr. Reddy’s Laboratories Inc.	U.S.A.	100% (7)
Dr. Reddy’s Laboratories Japan KK	Japan	100% (7)
Dr. Reddy’s Laboratories Kazakhstan LLP	Kazakhstan	100% (7)
Dr. Reddy’s Laboratories Malaysia Sdn. Bhd.	Malaysia	100% (7)
Dr. Reddy’s Laboratories New York, LLC	U.S.A.	100% (4)
Dr. Reddy’s Laboratories Philippines Inc.	Philippines	100% (7)
Dr. Reddy’s Laboratories Romania Srl	Romania	100% (7)
Dr. Reddy’s Laboratories SA	Switzerland	100%
Dr. Reddy’s Laboratories Taiwan Limited	Taiwan	100% (7)
Dr. Reddy’s Laboratories (Thailand) Limited	Thailand	100% (7)
Dr. Reddy’s Laboratories LLC, Ukraine	Ukraine	100% (7)
Dr. Reddy’s New Zealand Limited.	New Zealand	100% (7)
Dr. Reddy’s Srl	Italy	100% (8)
Dr. Reddy’s Bio-Sciences Limited	India	100%
Dr. Reddy’s Laboratories (Australia) Pty. Limited	Australia	100% (7)
Dr. Reddy’s Laboratories SAS	Colombia	100% (7)
Dr. Reddy's Netherlands B.V. (formerly Dr. Reddy’s Research and Development B.V.)	Netherlands	100% (9)
Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited	China	100% (7)
DRES Energy Private Limited	India	26% (10)
DRL Impex Limited	India	100% (11)
Dr. Reddy’s Formulations Limited	India	100%
Idea2Enterprises (India) Pvt. Limited	India	100%
Imperial Owners and Land Possessions Private Limited (Formerly, Imperial Credit Private Limited) (Dissolved on August 5, 2025)	India	100%
Industrias Quimicas Falcon de Mexico, S.A. de CV	Mexico	100%
Kunshan Rotam Reddy Pharmaceutical Co. Limited	China	51.33% (2)
Lacock Holdings Limited	Cyprus	100% (7)
Dr. Reddy’s Laboratories LLC	Russia	100% (7)(14)
Promius Pharma LLC	U.S.A.	100% (4)
Reddy Holding GmbH	Germany	100% (7)
Reddy Netherlands B.V.	Netherlands	100% (7)
Reddy Pharma Iberia SAU	Spain	100% (7)
Reddy Pharma Italia S.R.L.	Italy	100% (5)
Reddy Pharma SAS	France	100% (7)
Svaas Wellness Limited (Divested on April 7, 2026)	India	100%
Nimbus Health GmbH	Germany	100% (6)
Dr. Reddy’s Laboratories Jamaica Limited	Jamaica	100% (7)
O2 Renewable Energy IX Private Limited	India	26% (10)
Dr. Reddy’s and Nestle Health Science Limited (Formerly, Dr. Reddy’s Nutraceuticals Limited) (Refer t o Note 35.A of these consolidated financial statements for further details)	India	51%
Dr. Reddy’s Employees ESOS Trust	India	Refer to below footnote (13)
Cheminor Employees Welfare Trust	India	Refer to below footnote (13)

Dr. Reddy’s Research Foundation	India	Refer to below footnote (13)
Clean Renewable Energy KK 2A Private Limited (From July 31, 2024)	India	26.99% (10)
Northstar Switzerland SARL (From September 30, 2024)	Switzerland	100% (7)
North Star OpCo Limited (From September 30, 2024)	United Kingdom	100% (12)
North Star Sweden AB (From September 30, 2024)	Sweden	100% (12)
Dr. Reddy's Denmark ApS (From October 4, 2024)	Denmark	100% (7)
Dr. Reddy’s Finland Oy (From December 20, 2024)	Finland	100% (7)
Kunshan Rotam Reddy Medicine Company Limited	China	51.33% (2)(15)
Dr. Reddy’s Laboratories (Vietnam) Company Limited (From May 9, 2025)	Vietnam	100% (7)

(1)

Indirectly owned through Aurigene Oncology Limited (

Formerly, Aurigene Discovery Technologies Limited)

(2)

Kunshan Rotam Reddy Pharmaceutical Co. Limited and Kunshan Rotam Reddy Medicine Company Limited are subsidiaries as per

the

Indian Companies Act, 2013, as the Company holds a 51.33% stake. However, the Company accounts for this investment

in accordance with IFRS 11,

“Joint Arrangements”

using

the

equity

method and does not consolidate it in the Company’s financial statements.

(3)

Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited.

(4)

Indirectly owned through Dr. Reddy’s Laboratories Inc.

(5)

Indirectly owned through Lacock Holdings Limited.

(6)

Indirectly owned through Reddy Holding GmbH.

(7)

Indirectly owned through Dr. Reddy’s Laboratories SA.

(8)

Indirectly owned through Reddy Pharma Italia S.R.L.

(9)

Indirectly owned through Reddy Netherlands B.V.

(10)

Accounted

for

using

the

equity method as per IAS 28, “

Investments in Associates and Joint Ventures

”.

(11)

Indirectly owned through Idea2Enterprises (India) Pvt. Limited.

(12)

Indirectly owned through Northstar Switzerland SARL.

(13)

The Company does not have any equity interests in this entity but has significant influence or control over it.

(14)

45.19% held directly by Dr. Reddy’s Laboratories Limited.

(15)

Indirectly owned through Kunshan Rotam Reddy Pharmaceutical Co. Limited.